BioSpace News Archive

CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces additions to its international clinical team.

Based on encouraging Phase II results, patients with underlying CPB7 cirrhosis who lack a viable treatment option are now provided Namodenoson

HBM4003 is the First Fully Human Heavy Chain Only Antibody Ever to Enter Human Trials

Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced funding agreements with Royalty Pharma and its affiliate Pharmakon Advisors that, in aggregate, could bring in up to $270 million in capital, significantly strengthening Epizyme’s financial position and extending its operating runway into at least 2022.

The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE Healthcare portfolio for U.S. patients and radiologists.

Afya Limited, or Afya announced the acquisition, through its wholly-owned subsidiary Afya Participações S.A., of 100% of the total share capital of UniRedentor - Sociedade Universitária Redentor, or UniRedentor.

Advanced imaging technologies and integration of capabilities vital to deliver value-based care and drive revenue growth, finds Frost & Sullivan

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended September 30, 2019.

OpGen, Inc. (Nasdaq: OPGN) reported an update on the business of Curetis GmbH, the other party to the planned business combination with OpGen. On October 28, 2019, Curetis, N.V. announced that its wholly-owned subsidiary Ares Genetics GmbH (“Ares Genetics”) has launched an early access program for its novel, artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular antibiotic susceptibility test (AST).

Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and as J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences